Toutes les études
RecrutementOBSERVATIONNEL

A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple Countries

This study is about a rare condition called Hereditary Angioedema (HAE). HAE causes sudden, temporary swelling in different parts of the body. This particular study focuses on children aged 2-11 who have a specific type of HAE (called HAE-C1INH deficiency) and are already taking a medicine called lanadelumab (also known as Takhzyro) to help prevent these swelling attacks. Researchers want to understand how well lanadelumab is working for these children in their everyday lives. They will look at existing medical records to see how long children go without HAE attacks while on the medicine. They will also learn about its safety and how often children need to see a doctor because of their HAE. No new treatments or interventions will be given as part of this study; all information comes from past medical notes.

En un coup d'œil

Statut
Recrutement
Sponsor
Takeda
Objectif d'inscription
40
Démarrer
05 Feb 2026
Achèvement estimé
30 juin 2026

De quoi parle cette étude ?

This study is focused on children who have a rare condition called Hereditary Angioedema (HAE), specifically a type where the body doesn't make enough of a protein called C1 inhibitor. HAE causes sudden and often painful swelling under the skin or inside the body, such as in the tummy, throat, or private areas. This swelling is different from allergies because it doesn't cause itching or hives.

Many children with this type of HAE take a medicine called lanadelumab (you might know it as Takhzyro) to help prevent these swelling attacks from happening. This study wants to understand how effective lanadelumab really is in the day-to-day lives of these children. Researchers will look at existing medical records to see how long children taking lanadelumab go between HAE attacks. They also want to understand the general health of these children, how safe the medicine appears, and how often they need to visit doctors or hospitals because of their HAE.

It's important to know that no new treatments will be given in this study. Researchers will simply look at information that is already in children's medical files. This means there are no extra appointments, tests, or medicines involved beyond the care your child is already receiving. The findings from this study will help doctors and families better understand how lanadelumab helps children with HAE in the real world.

Points clés

  • This study helps us understand how a medicine already in use, Takhzyro (lanadelumab), works for children with a rare swelling condition (HAE).
  • It focuses on children aged 2-11 who are already taking Takhzyro to prevent swelling attacks.
  • Researchers will review existing medical records to learn about attack frequency, safety, and healthcare use.
  • No new treatments, tests, or appointments are involved, only past medical data is used.
  • The findings will help improve care and understanding for children with HAE in the future.

Qui peut être éligible ?

For a child to be included in this study, they would need to meet a few specific requirements. Firstly, they must be between 2 and 11 years old when they first started taking the medicine lanadelumab, and expected to have at least six months of medical information recorded after starting it before they turn 12. Secondly, a doctor must have officially diagnosed them with the specific type of HAE called HAE-C1INH deficiency. Thirdly, they must have started taking lanadelumab as a long-term preventative treatment during a specific time period set by the study.

Also, your child's medical records must clearly show they had HAE attacks both before and after they started taking lanadelumab. This helps researchers compare how often attacks happened before and after starting the medicine. Before joining, either you or your child (if they are old enough and local rules require it) would need to agree to their medical records being used for the study.

Some children would not be included. For example, if your child was already taking part in another study that involved a new medicine (either lanadelumab or another drug) or a new medical device at the time they started this study. Also, if your child hadn't had any HAE attacks in the 12 months before they started taking lanadelumab, they would not be eligible for this study.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Is your child aged between 2 and 11 years?
  2. Has a doctor officially diagnosed your child with HAE due to low C1 inhibitor protein levels?
  3. Is your child currently taking a medicine called Takhzyro (lanadelumab) to prevent HAE attacks?
  4. Does your child's medical record show they had HAE attacks both before and after starting Takhzyro?
  5. Has your child not been involved in another new drug or device study recently?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If your child's existing medical records are chosen for this study, there is no active participation required from you or your child. This isn't a study where your child will be given a new medicine or asked to visit a clinic for extra tests. Instead, researchers will be looking back at medical information, like doctor's notes, hospital visits, and details about their HAE attacks, that already exists in their health records. They will be gathering this information to understand how lanadelumab has been working for children with HAE over time. This means that for participants, there are no extra appointments, no changes to their current medication, and no additional follow-up required beyond their usual medical care.

Risques et avantages potentiels

Since this study only involves looking back at existing medical records and no new treatments or procedures are being carried out, there are no direct medical risks to your child from taking part. The benefit of taking part is that the information from your child's medical records will help researchers and doctors better understand how lanadelumab works for children with HAE in real-life situations. This improved understanding could potentially help other children with HAE in the future. As a parent or guardian, you always have the right to withdraw your consent for your child's de-identified medical data to be used in the study at any time.

Locations (24)

  • Hospital de Ninos Sor Maria Ludovica
    Code postal vérifié
    La Plata, Argentina· Pas encore en recrutement
  • Centro de Alergia e Inmunologia Clinica Mar del Plata
    Code postal vérifié
    Mar del Plata, Argentina· Pas encore en recrutement
  • Hospital de Pediatria S.A.M.I.C.- Prof. Dr. Juan P. Garrahan
    Ville uniquement
    Ciudad de Buenos Aires, Argentina· Pas encore en recrutement
  • Hospital Italiano de Buenos Aires
    Code postal vérifié
    Buenos Aires, Argentine· Recrutement
  • Sanatorio de la Canada-Cordoba
    Code postal vérifié
    Córdoba, Argentine· Recrutement
  • AP-HM- Hopital de La Timone
    Code postal vérifié
    Marseille, France· Recrutement
  • CHU de Grenoble Alpes - Hopital Couple-Enfant
    Code postal vérifié
    La Tronche, France· Recrutement
  • AP-HP - Hopital Armand Trousseau
    Code postal vérifié
    Paris, France· Recrutement
  • Universitatsklinikum Ulm
    Code postal vérifié
    Ulm, Germany· Pas encore en recrutement
  • Universitatsklinikum Frankfurt am Main
    Code postal vérifié
    Frankfurt am Main, Germany· Pas encore en recrutement
  • Hamophilie Zentrum Rhein Main GmbH
    Code postal vérifié
    Frankfurt am Main, Germany· Recrutement
  • Universitatsklinikum Munster
    Code postal vérifié
    Münster, Germany· Recrutement

Questions fréquentes

Qu'est-ce que l'Angio-œdème Héréditaire (AOH) ?

HAE is a rare genetic condition that causes sudden and unpredictable swelling attacks in different parts of the body, like the face, hands, feet, or internal organs, but without itching or hives.

What is lanadelumab (Takhzyro)?

Lanadelumab, also known as Takhzyro, is a medicine used to help prevent swelling attacks in people with Hereditary Angioedema (HAE).

Will my child receive any new medication in this study?

No, this study only looks at existing medical records. Your child will not receive any new medication or intervention as part of this study.

What kind of information will researchers look at?

Researchers will look at information already in your child's medical records, such as their HAE diagnosis, when they started lanadelumab, details about their HAE attacks, and any hospital visits or doctor appointments related to their condition.

How long will my child be involved in the study?

Your child is not actively involved in the study. Researchers will simply collect information from their existing medical records. There's no extra time commitment for you or your child.

Comment en savoir plus

Takeda Contact

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "A Study of Lanadelumab in Children With Hereditary Angioedem… vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.